SESSION III: ACUTE MYELOID LEUKEMIA

Session Chair: Farhad Ravandi and Bob Löwenberg

Update on Menin Inhibitors | Eunice Wang, MD | Roswell Park Cancer Center, Buffalo, New York, USA

FLT3 Mutated AML Unanswered Questions | Mark J Levis, MD, PhD | Johns Hopkins University, Baltimore, Maryland, USA

MRD as a Surrogate Endpoint for AML Therapy | Christopher S Hourigan, MD, DPhil | Virginia Tech FBRI Cancer Research Center, Washington, DC, USA

DEBATE: Azacytidine plus Venetoclax Should Be Prescribed As Listed On the Label | Keith Pratz, MD | University of Pennsylvania, Philadelphia, Pennsylvania, USA

DEBATE: Dose Reductions in Azacytidine plus Venetoclax Are Not Detrimental | Stéphane De Botton, MD, PhD | Institut de Cancérologie Gustave Roussy, Villejuif, France

Which Patients Over 70 With AML Should Be Transplanted in the First CR | Charles Craddock, CBE, FRCP, FRCPath | University of Birmingham, Birmingham, United Kingdom

Immune/Cellular Therapy in AML | Marion Subklewe, MD | Ludwig-Maximilians-University of Munich, Munich, Germany

International Expansion of Modern AML Therapy | Eduardo M Rego, MD | University of São Paulo, São Paulo, Brazil

Oral Abstract | AML-584: Aspirin's Intriguing Role in Leukemia's In-Hospital Hemorrhagic and Thrombotic Events: A Nationwide Analysis | Jayalekshmi Jayakumar, MD | The Brooklyn Hospital Center, Brooklyn, New York, USA